The European Commission has approved the regime in combination of active ingredients saxagliptin and dapagliflozine, registered as Qtern by the Biopharmaceutical Company Astrazeneca and indicated for the treatment of type II diabetes.
According to the aforementioned laboratory, the authorization occurred "in tablets, in the 28 member countries of the European Union, more Iceland, Liechtenstein and Norway.""The combination of fixed dose of saxagliptin and dapagliflozine is the first combination of DPP-4I/SGLT-2i that has been approved in Europe," he explains.
“This treatment is indicated in adults with type II diabetes, from 18 years, to improve blood glucose control when metformin and/or a sulfonylurea and one of the individual components of this combination by themselves do not get adequate controlof blood glucose or when the patient is already being treated with the free combination of saxagliptin and dapagliflozine, ”says Astrazeneca.
In this context, the vice president and director of cardiovascular and metabolic diseases of the Department of Global Medicines Development of the aforementioned biopharmaceutical, Elisabeth Björk, declares that “almost half of patients with type II diabetes does not reach their therapeutic objective and therefore, therefore, there is a risk of developing complications due to hyperglycemia. ”
"This treatment is the first combined product of its class that has been approved in Europe and an important new therapeutic option to help patients control the disease through a powerful reduction in glucosylated hemoglobin (HBA1C)," concludes the representative of Astrazeneca.
